New Key Statistics Module, Z-Score and F-Score
NAS:IPHA Key Ratios
| Market Cap $ M | 245.07 |
| Enterprise Value $ M | 228.79 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 119.80 |
| Price/Book | -- |
| Price/Sales | 59.48 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 3.00 |
| EPS (TTM) $ | -0.64 |
| Beneish M-Score | 12.92 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -3.99 |
| EV-to-EBITDA | -4.45 |
| PEG | -- |
| Shares Outstanding M | 111.70 |
| Net Margin (%) | -1,764.51 |
| Operating Margin % | -1,916.94 |
| Pre-tax Margin (%) | -1,764.51 |
| Quick Ratio | 1.27 |
| Current Ratio | 1.27 |
| ROA % (ttm) | -55.31 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -127.96 |
| Dividend Yield % | -- |
| Altman Z-Score | -10.59 |
IPHA Number of Guru Trades
IPHA Volume of Guru Trades
Gurus Latest Trades with NAS:IPHA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:IPHA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Innate Pharma SA Insider Transactions
No Available Data
News about NAS:IPHA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers